Theravance Biopharma (TBPH) Scheduled to Post Earnings on Monday

Posted by Defense World Staff on May 6th, 2023

Theravance Biopharma (NASDAQ:TBPH – Get Rating) is scheduled to be releasing its earnings data after the market closes on Monday, May 8th. Analysts expect Theravance Biopharma to post earnings of ($0.27) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Theravance Biopharma Trading Up 0.8 %

Shares of TBPH opened at $11.33 on Friday. Theravance Biopharma has a 12 month low of $7.53 and a 12 month high of $12.03. The firm has a fifty day simple moving average of $10.85 and a 200 day simple moving average of $10.72. The stock has a market capitalization of $716.40 million, a price-to-earnings ratio of 0.98 and a beta of 0.50.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $10.20, for a total value of $40,800.00. Following the completion of the sale, the senior vice president now owns 360,190 shares in the company, valued at $3,673,938. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP Richard A. Graham sold 2,323 shares of the stock in a transaction dated Friday, April 14th. The shares were sold at an average price of $11.88, for a total value of $27,597.24. Following the transaction, the senior vice president now directly owns 369,494 shares of the company’s stock, valued at $4,389,588.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $10.20, for a total transaction of $40,800.00. Following the completion of the transaction, the senior vice president now directly owns 360,190 shares in the company, valued at $3,673,938. The disclosure for this sale can be found here. Insiders sold a total of 10,969 shares of company stock worth $115,717 over the last quarter. 5.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently modified their holdings of TBPH. UBS Group AG raised its position in shares of Theravance Biopharma by 45.0% in the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,101 shares during the period. Point72 Middle East FZE bought a new position in shares of Theravance Biopharma in the fourth quarter valued at about $41,000. Quantbot Technologies LP bought a new position in shares of Theravance Biopharma in the second quarter valued at about $62,000. Royal Bank of Canada raised its position in shares of Theravance Biopharma by 1,330.7% in the third quarter. Royal Bank of Canada now owns 6,610 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 6,148 shares during the period. Finally, Acadian Asset Management LLC raised its position in shares of Theravance Biopharma by 51.6% in the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,818 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on TBPH. HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 28th. StockNews.com initiated coverage on shares of Theravance Biopharma in a research note on Thursday, March 16th. They issued a “hold” rating for the company.

Theravance Biopharma Company Profile

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.